Abstract Amyotrophic lateral sclerosis (ALS) is a progressive and fatal degenerative disorder of motor neurons. The cause of this degeneration is unknown, and different causal hypotheses include genetic, viral, traumatic and environmental mechanisms. In this study, we have analyzed metal concentrations in cerebrospinal fluid (CSF) and blood plasma in a well-defined cohort (n017) of ALS patients diagnosed with quantitative electromyography. Metal analyses were performed with high-resolution inductively coupled plasma mass spectrometry. Statistically significant higher concentrations of manganese, aluminium, cadmium, cobalt, copper, zinc, lead, vanadium and uranium were found in ALS CSF compared to control CSF. We also report higher concentrations of these metals in ALS CSF than in ALS blood plasma, which indicate mechanisms of accumulation, e.g. inward directed transport. A pattern of multiple toxic metals is seen in ALS CSF. The results support the hypothesis that metals with neurotoxic effects are involved in the pathogenesis of ALS.
Introduction
Amyotrophic lateral sclerosis (ALS) is a disorder of the nervous system. The disease is characterized by degeneration of anterior horn cells of the spinal cord [1] . Muscle atrophy and denervation are prominent findings, and quantitative electromyography (QEMG) is needed for definite diagnosis. The cause of ALS is still not known. Autopsy studies of ALS cases show sclerosis in the corticospinal tracts, and in some cases, cerebral frontal lobes are involved in the degeneration. Sensory nerve cells are often spared. Early in the clinical course of ALS, even before clinical symptoms, axonal loss can be detected by QEMG as positive sharp waves and fibrillation potentials are noted in registrations from skeletal muscles [2] .
The aetiology of motor neuron degeneration in ALS is unknown. Viral, genetic, inflammatory and toxic mechanisms of nerve cell degeneration have been discussed [3] . Some 10 % of ALS cases are familiar, and genetic aberrations have been described in these familial cases, most frequently occurring in the superoxide dismutase (SOD1) enzyme leading to zinc-deficient SOD variants possibly involved in familial ALS pathogenesis. Cases not involving these well-characterized genetic deviations are described as sporadic. Various metals contributing to the development of ALS have been proposed [4, 5] . Aluminium, manganese and other metals, or mineral/metal imbalances, have been implicated in the hyperendemic foci of ALS in Guam and the Kii Peninsula of Japan [6] [7] [8] . An increasing trend in ALS prevalence in the world [9, 10] has been noted; however, the search for a unifying explanation to the relentless and always lethal course of the disease has been unsuccessful despite intense research efforts over decades.
The nerve cells of the lateral columns, degenerating in ALS, are surrounded by cerebrospinal fluid (CSF) in equilibrium with the extracellular fluid (ECF) between neurons. The choroid plexus anatomically represents the barrier between blood and CSF, which can be considered an ultrafiltrate from plasma across this barrier. Similar although not identical protein composition of ECF and CSF [11] indicates that ECF is also an ultrafiltrate from CSF. Thus, the metal concentrations in CSF reflect concentrations in the fluid surrounding neurons in dynamic equilibrium with the cytoplasm of the nerve cell across the cell membrane. In this study, sampling of CSF was performed and blood samples drawn simultaneously, allowing for comparisons and some conclusions about blood-brain barrier (BBB) properties. Accumulation of neurotoxic metal in nerve cells of the spinal cord and/or in CSF could explain some of the features of ALS.
The aim of this study was to investigate metal concentrations in CSF and blood plasma in patients diagnosed with ALS using high-resolution inductively coupled plasma mass spectrometry (HR-ICP-MS).
Materials and Methods

Study Population
Consecutive patients referred for electrophysiological investigations under the suspicion of ALS were recruited for the study. Patients were unrelated and came from all regions of Norway but mostly from the Oslo area. Only patients meeting the diagnostic criteria of Arlie House [12] for definite ALS were included. Thus, first motor neuron signs as well as second motor neuron signs and progression were present. Thorough neurophysiologic studies were performed twice and showed findings [13] consistent with the diagnosis of ALS in each included case. Every patient was investigated at separate occasions independently by two experienced neurologists before final diagnosis. Each patient was followed for 2 years or more to ensure clinical progression confirming the diagnosis of ALS.
Controls were spouses or friends of ALS patients included in the study, as well as medical students and outpatients at the neurological clinic seeking medical attendance for minor complaints. Complaints such as transient headache or tingling sensations or worries for serious illness were considered minor. Routine laboratory testing was normal in this category. The controls were followed for at least 2 years for unexpected exacerbations, and no such events occurred.
The clinical characteristics of the study population have been described previously [14, 15] . In summary, 17 patients with definite diagnosis of ALS according to the criteria of the World Federation of Neurology were compared to ten controls without age matching. Three out of 17 ALS cases were bulbar. Mean age was 64 years (range, 47-85) for ALS cases and 45 years (range, 26-77) for controls. The M/F sex ratio was 1.8 for cases and 1.5 for controls. Main occupations are given in Table 1 in [15] .
Subjects gave informed consent prior to procedures. Ethical approval was given by the local ethical committee (KI forskningskommitté Nord 03-353) in Stockholm and the National Committee for Research Ethics in Norway (REK sør-øst 470-03140).
Sampling
Spinal tap was performed in the supine position from lumbar levels using a standard Spirocan 0.9×88-mm syringe with bevel according to Quincke (B. Braun Melsungen AG, Germany). Skin was disinfected using 4 % chlorhexidine gluconate in ethanol without phenolic red (Fresnius Kabi Norge AS, Oslo, Norway). No suction device or plastic tubing was used. CSF was collected dripping in free air in 1 ml aliquots into polypropylene CryoTubes (NUNC, Roskilde, Denmark) with stopper and silicone gasket rinsed twice with ultrapure water (ELGA purification system, ELGA Lab Water, Lane End, UK) using a mechanic whirlmixer. When performed in sequence with a routine spinal tap, the CSF samples for metal analysis were collected after the routine samples. When performed alone, the first 3 ml of CSF were allowed to drip and were discarded before the actual sampling for metal analysis. Punctuation bleeding was checked for by visual inspection. Blood was collected from an antecubital vein immediately after the spinal tap, using a 21-G needle and 7.5-ml lithium heparin polypropylene tubes (Sarstedt S Monovette system, Sarstedt AG & Co., Nümbrecht, Germany) dedicated for metal analysis. After centrifugation at 3,000 rpm for 10 min, aliquots of 1.5 ml plasma were transferred with a clear plastic pipette to rinsed CryoTubes. The paired samples of CSF and plasma were frozen at −18°C and then transferred to −86°C and stored until further analysis. During sampling of CSF and blood, thorough cleanliness routines were adopted for the sampling room, equipment, bed and patient to avoid contamination from external sources. Thorough hand washing was performed.
Neurophysiologic Evaluations
Electrodiagnostic evaluations included QEMG with concentric needle electrode and neurography with surface electrodes. Motor unit potentials were examined for stability and amplitude, duration and complexity of the signal. Fibrillation potentials and positive sharp waves were recorded. Fasciculation potentials were recorded and evaluated for complexity and stability. Sensory nerve conduction studies included orthodromic conduction from fingers to wrist for the ulnar and median nerves and antidromic from below the knee to lateral malleolus for the sural nerves. Motor nerve conduction in median, ulnar, radial, tibial and peroneal nerves was studied using routine methods. Temperature was measured and kept above 29°C in the upper extremity and 27°C in the lower. Keypoint electrodiagnostic system was used.
Metal Analysis HR-ICP-MS analyses were performed [14] using a Thermo Finnigan model Element 2 instrument (Germany). Samples were introduced using a CETAC ASX 500 autosampler with a peristaltic pump. The instrument was equipped with a concentric Meinhart nebulizer connected to a Scott PFA spray chamber, platinum skimmer and interface cones and a quartz burner with a guard electrode. Calibration with 0.6-M HNO3 solutions of matrix-matched multimetal standards was performed. To check for instrumental drift, one of these multimetal standards with known metal concentrations was analyzed for every ten samples. Certified reference materials (SPSSW1, SPS-SW-2, Spectrapure, Norway) were analyzed at the beginning and end of each analytical sequence. As HR-ICP-MS was used, no problems with background interferences were encountered. Known isobaric overlaps were corrected in the standard software, and known interferences between oxides and metals (e.g. molybdenum oxide as interference for cadmium) were corrected. Resolution mode for each isotope was selected for each run in order to obtain maximum sensitivity with minimum RSD (relative standard deviation of measurement ).
Quality Control
For ultra-trace metal analysis of clinical samples, controlling and minimizing all possible sources of contamination is mandatory [16] . To assess possible contamination during sample preparation, appropriate blank samples of ultrapure water with HNO 3 were prepared using the same procedure as for the samples. All blank levels obtained were negligible.
Reference material for metals in CSF is not commercially available, and thus, accuracy was verified by analyzing the certified reference material Seronorm Serum Level 1 (Sero, Norway). The instrumental detection limits (IDL) for this method are very low (Table 1) , and in practice, the detection limits (DL) for most metals are therefore determined by the metal concentrations present in the blank samples.
Statistical Methods
The median test was used to evaluate if the median concentration of metals in CSF and plasma differed between ALS patients and controls. Due to the heavy right tail distribution of the outcome variables, the difference in metal concentrations between ALS and controls was evaluated by the percentage of observations above the overall median (OM). By adding all values for ALS cases to all values for controls and finding the median value among the total, the OM was calculated. As the median is insensitive to outliers, observations with very high concentration, as present in this material, will not yield misleading results when evaluated by the median test. Multiple comparison corrections were not applied. Confidence intervals of 95 % and hypothesis tests for the difference in proportion above OM between the groups was carried out using an exact version of the score statistic with a single two-sided inversion [17, 18] . Nonparametric statistics were thus used to rank each metal according to its ability to separate the ALS patient group from the control group. The OM value was calculated for each metal, and the deviation from that median was expressed in percent units and used to describe the separation of the ALS group from the control group. Each metal was tested against the null hypothesis that the median was the same across the categories ALS or control using the independent samples median test. The null hypothesis was rejected when an exact significance <0.05 was reached. When rejected, the test was considered statistically significant. The number of cases above OM is presented in a pyramid graph split by metal and ALS/controls (Fig. 1) . Furthermore, the pyramid graph is sorted by the number of controls above the overall median to visually categorize metals regarding concentrations of the metal. Graphs were prepared and analyses performed using the IBM SPSS statistics software (version 18.0, SPSS Inc., Chicago, IL, USA) and StatXact 7 (Cytel Software Corporation, Cambridge, MA, USA).
Results
Statistically significant higher concentrations of Mn, Al, Cd, Co, Cu, Zn, Pb, V and U were found in CSF from ALS patients than in CSF from controls ( Fig. 1 and Table 2 ).
Three separate groups according to statistical separating power could be distinguished ( (Fig. 1) . High levels of mercury and arsenic were also found in some of the control individuals.
Boxplots describing the first group of metals are given in Fig. 2 , and describing the second group, in Fig. 3 . Uranium showed unique statistics and is shown separately in Fig. 4 .
In order to get an overview of the presence of every metal above a given concentration in CSF, a cut-off limit was set at 1 standard deviation (1SD) above the mean for the combined cases and controls. When concentrations at or above the given limit were found, that metal was indicated with a small circle. From literature data, toxic properties of all measured metals were evaluated. Metals with known toxicity to nerve cells, these metals also present in concentrations at or above 1SD, were indicated with a larger triangle (Fig. 5) . The metals Al, Mn, As, Hg and Pb, indicated with triangles, are established neurotoxicants [19] [20] [21] [22] [23] . In addition to these metals, also Cd [24] and U [25] [26] [27] have shown some toxic effects towards nerve cells.
Metal concentrations (see Supplementary material) at or above the overall mean +1SD was noted in 77 observations in the 17 ALS cases (453 %) and in 19 observations in the ten controls (190 %; Fig. 5 ). When metals regarded as neurotoxic (Al, Mn, As, Hg, Pb, Cd and U) were considered separately, 35 observations in 17 ALS cases (206 %) were noted, compared to five observations in ten controls (50 %). All individuals with CSF concentrations of U at or above the overall mean +1SD were ALS cases (Fig. 5) . In summary, metals with neurotoxic properties were more abundant in CSF from ALS cases than in CSF from controls. Fig. 1 Results of median test. The proportion of CSF metal concentration measurements that fall above the combined median value (OM overall median) for both ALS case values and control values is shown. Individual metals are reported from top to bottom in order of increasing ability to discriminate between groups. Length of bar represents percentage units with 100 % as maximum Median values and ranges for blood plasma concentrations of all measured metals from ALS patients and controls are given in Table 3 . Slightly elevated mercury concentrations can be noted in ALS blood plasma compared to controls, and Ag median is approximately two times higher in ALS than in controls. The median values for all other measured metals are similar in blood plasma from ALS patients and in controls. Thus, the increase in metals with known neurotoxicity, noted in CSF from patients with ALS, is not reflected in blood plasma.
Discussion
In this study, CSF concentrations of the metals Mn, Al, Cd, Co, Cu, Zn, Pb, V and U were statistically significantly higher in subjects with ALS than in control individuals. Some of these metals are well-characterized neurotoxicants.
Comparisons to other neurodegenerative diseases, such as manganese in Parkinson disease and the possible role of aluminium in Alzheimer disease, have recently been presented [24] . Similarities between these entities exist, such as frontal lobe involvement in ALS [28] with dementia and muscle wasting, and parkinsonian comorbidity with ALS giving rise to cases with both tremor and rigidity and muscle wasting. Metal intoxications involving several metal combinations resulting in different clinical profiles is one possible explanation to these overlap situations. The presence of metals in CSF is however not tantamount to axonal damage caused by these very metals, and further analyses of the mechanisms of metal neurotoxicity are warranted. The interpretation that observed elevated metal concentrations are a consequence of some other disease process rather than the cause of disease is also valid.
In contrast to the increased metal levels in CSF of the ALS patients, a corresponding elevation of Mn, Al, Cd, Co, Cu, Zn, Pb, V and U in blood plasma was not noted. Barrier systems [29] protect the spinal cord and the CSF compartment from chemical injury, e.g. from metals. Some metals such as Mn seem to have active inward transporters [30] potentially contributing to the Mn accumulation in CSF found in our study. The blood-CSF barrier does not seem to protect against U penetrating into the CSF; rather, an accumulation of U too can be suspected, as almost every CSF-U value is higher than the corresponding blood plasma-U value. To what extent transporters for the other metals, significantly increased in ALS CSF (Pb, Al, Cd, Cu, Co, Zn and V), are active in ALS remains to be elucidated. Respiratory exposure to mercury vapour in primate or rodent causes accumulation of the metal in anterior horn cells of the spinal cord implicating impaired barrier protection [31] . Lead is known to accumulate in the choroid plexus. The possibility in ALS of injuries to the barrier systems themselves from toxic metal molecules is another possibility to consider.
In an attempt to evaluate barrier function, metal concentrations in CSF were divided by the corresponding concentrations in blood plasma to produce C/B ratios. The average C/B ratios for Al, V, U, Mn, Cr and Ni were about twice as high in ALS cases as in controls. These metals showed C/B ratios above the value 1 both for ALS cases and for controls, i.e. higher concentrations in CSF than in plasma, indicating possible accumulation inside of the BBB. Average ratios for Mo, Au, Hg and Fe were below the value 1, i.e. higher concentrations in plasma than in CSF, both for ALS cases and for controls (data in Supplementary material).
Average C/B ratios above 1 for ALS cases but below 1 for controls were found for Co and Cd. Higher concentrations in plasma than in CSF, although with higher C/B ratios among ALS cases, were noted for Zn and As. Selenium showed approximately the same average ratios for CSF as for plasma, as did Au, Mg, Cu, Rb, Sr, Ag and Fe. Copper showed the lowest ratios both for ALS cases and for controls. C/B ratios are produced by dividing a CSF concentration value with a certain variation (CV%) by another value with different variation, thereby increasing the level of uncertainty of the ratio. The results should be interpreted with caution.
Individual Metals
The metals in the first group, where the difference in concentrations between ALS cases and controls did reach statistical significance, were Al, V, Mn, Co, Cu, Zn, Cd, Pb and U (Group 1). Metals in this first group are all discussed below in more detail. They were found in CSF in a higher proportion in ALS cases than in controls, expressed here as percent for each metal. When indicated as found, the concentration value in CSF was defined as above or at a cut-off limit set to 1 standard deviation (1SD) above the mean for the combined cases and controls for that metal (Fig. 5) .
Aluminium (Al) was in our study, using the 1SD criterion, found in CSF from 17 % of ALS cases and not found in CSF from control individuals (Fig. 5) . Aluminium is the most common metal in the Earth's crust and has found increasing industrial use. Al is a well-known neurotoxicant. Encephalopathy from Al-containing dialysis fluids is described, and nervous system symptoms from Al medical procedures such as parenteral nutrition, bone cement use and irrigation of the urine bladder are described [32] . High Al concentrations are noted at autopsy in brains from AD patients [33] , but replication studies are inconsistent. Motor neuron degeneration has been shown in mice following Al hydroxide injections [34] . Motor neuron degeneration with neurofibrillary tangle formation, chromatolysis and abnormal localization of nuclei, resembling ALS pathology, is observed in mice after Al injection [35] .
Vanadium (V) was, using the 1SD criterion, found in CSF from 12 % of cases and not found in controls. Vanadium is a metal used in steel alloys to improve corrosion resistance, and V is not part of any normal cellular processes. Fossil fuel combustion and automobile converters are common sources of Vemission into the atmosphere [36] . Inhalation of V caused changes in excitability of tibial musculature in rats. Acute V intoxication in experimental animals causes death preceded by paralysis of the hind legs. Vanadium exerts neurotoxic effects in dopaminergic neuronal cells [37] .
Manganese (Mn) was, using the 1SD criterion, found in CSF from 30 % of cases and not found in controls. All individuals showing Mn values above 1SD were ALS cases. Manganese is ubiquitous in soil, air, water and food. It is necessary for proper nerve cell function in low concentrations, but in higher concentrations neurotoxic. Food is the major source of intake, and Mn homeostasis is regulated by hepatic excretion. Neurotoxic properties of Mn are well described [38] . Mn crosses BBB and accumulates in the central nervous system with longer half-life within nervous tissue. Cumulative mechanisms of neurotoxicity seem to cause manganism with progressive irreversible brain impairment. Similarities to Parkinson disease have been discussed [39] . Occupational exposure to Mn causes manganism rather than ALS. Mn accumulation primarily in nuclei of cultured brain cells has been described [40] . Elevated Mn concentrations are reported [41] in spinal cord sections from ALS patients. Cobalt (Co) was, using the 1SD criterion, found in CSF from 18 % of cases and not found in controls. Cobalt is essential to mammals in the form of methylcobalamin. Cobalt exposure affects the respiratory system and haematopoiesis, but no reports on human nervous system effects of Co have been published; however, motor neuron-like cell lines exposed to cobalt chloride showed signs of oxidative toxicity associated with motor neuron death in ALS [42] . Fig. 5 Distribution of metals in CSF from ALS cases (n017) and controls (n010). A concentration of 1 standard deviation (1SD) or more above the mean for the combined cases and controls for that metal is indicated by a small circle. Metals with known neurotoxic properties, also present in concentrations at or above 1SD, are marked with a larger triangle Copper (Cu) was, using the 1SD criterion, found in CSF from 30 % of cases and not found in controls.
Copper is an essential metal, and is a constituent of several enzymes, e.g. SOD1 and cytochrome c oxidase, but is toxic in higher concentrations. Cu is used in electrical wires, water pipes, fungicides, contraceptives and in alloys such as brass. Cu concentrations are effectively regulated, and mutations in Cu regulatory proteins cause Menkes disease and Wilson's disease, both affecting the nervous system. Inorganic copper, as found in drinking water and in vitamin supplements, is potentially toxic to the brain possibly contributing to AD development [43] . One case of early onset ALS with elevated Cu levels has been described [44] .
Zinc (Zn) was, using the 1SD criterion, found in CSF from 23 % of cases and 10 % of controls. Zinc is a metal essential for life; however, excess intake of Zn impairs Cu availability, probably through metallothionein-related mechanisms. Zn is necessary for brain development and function and is essential for nerve conduction. No ALS cases associated with Zn deficiency or elevated Zn concentrations have been described, but some hypotheses relate Zn deficiency to ALS [45] . Both Cu and Zn are vital components of a SOD1 enzyme, and mutations in the SOD gene have been shown in most familial ALS cases, which make up about 10 % of the total number of ALS cases.
Cadmium (Cd) was, using the 1SD criterion, found in CSF from 35 % of cases and not found in controls. Cadmium is not part of any normal cellular processes, and Cd is toxic at very low exposure levels [46] . It is used in painting pigments, in plating, plastics, batteries and welding. Cd exposure through tobacco smoking is a health concern. Cd is transported in plasma largely bound to metallothionein (MT), and Cd stimulates MT synthesis [47] . No difference in blood Cd levels between AD patients and controls could be found in a Swedish study [48] . Cd concentrations were markedly and significantly elevated both in gray and white matter in formalin-fixed brain tissue from Guam ALS cases [7] . An ALS patient with 9 years of Cd exposure in a Ni-Cd battery factory has been described [49] .
Lead (Pb) was, using the 1SD criterion, found in CSF from 30 % of cases and 10 % of controls. Lead exposures from paint, gasoline, ceramics, can solderings, plumbing and tobacco are decreasing however still of some importance. Pb exposure may cause encephalopathy, and lowdose, long-time exposure to Pb in children has been linked to reduced intellectual performance. Exposure to lead also causes a motor neuropathy characterized by weakness and atrophy of skeletal muscles without sensory involvement. Chronic administration of lead in chicken results in a syndrome involving muscle weakness, atrophy and motor nerve degeneration comparable to human ALS [50] . The spinal origin of the neuropathy following chronic low-dose lead intoxications in humans has been debated for more than a century, and the historical observations [51] from a series of 1,213 lead-intoxicated patients stating the anterior horn of the spinal cord as the site of injury are still valid. A recent large NIEHS study [52] reported elevated blood lead levels among ALS cases compared to controls (p<0.0001, age-adjusted).
Increased bone lead concentrations have recently been reported associated with longer survival in ALS patients [53] . In mice expressing an ALS-linked SOD mutation [54] , low-level lead exposure actually resulted in longer survival and increased expression of vascular endothelial growth factor (VEGF). A 39-year-old factory worker handling lead oxide showed atrophy, spasticity and fasciculations of lower extremities after excess lead exposure and subsequently died from ALS [55] . Uranium (U) in CSF was, using the 1SD criterion, found in 47 % of cases and not found in controls. Enriched U ( 235 U) is the source for energy production in nuclear reactors and weapons. Uranium exposure from water and food may reach 0.9-1.5 μg/day [56] . Adverse health effects of U involve combined chemical and radiological mechanisms with chemical toxicity being most important [57] . Absorption of U is low regardless of exposure route and highly dependent on its solubility. Inhaled U dust particles of low solubility can be retained for years. The main target for U toxicity is the kidney where atrophy and necrosis of glomerular walls occur. Accumulation in rat brain after respiratory U exposure is heterogeneous with the higher concentrations in the olfactory bulbs and cerebellum [58] . Rats surgically implanted with U pellets showed after 6 months presence of U in the cortex, midbrain and cerebellum suggesting that U preferentially accumulates in specific brain regions after exposure [25] . Geochemical conditions in Sweden, having the same natural occurrence of uranium as Norway, imply elevated U in drinking water. Regulatory agencies in Sweden have limited the highest allowed concentration of uranium in drinking water to 15 μg/l [59] . Laboratory experiments [25] using organisms such as Caenorhabditis elegans and rats have concluded with low acute neurotoxic potential of U following exposure and a protective potential from metallothionein. No connection between U and ALS has previously been reported.
Synergistic Effects and Patterns of Metal Distribution
Our study shows elevated concentrations of several metals with known toxicity to the nervous system in CSF from ALS patients. Additive effects for metal toxicity have been observed in toxicity assays [60] . Recent observations [61] on rat astrocytes also show that a mixture of As, Cd and Pb has the capacity to induce synergistic toxicity and may compromise the BBB. In the clinical setting, simultaneous exposure to multiple metals through the air, food and water can be expected. In our study, especially different combinations of metals in the first group (Al, V, Mn, Co, Cu, Zn, Cd, Pb and U) should be emphasized.
It is necessary to consider the possible role of toxic synergisms and interactions between several metals in the molecular mechanisms that lead to ALS. Metal synergisms may account for the clinical variability seen in the ALS distribution of weakness and time span of progression. Each metal has a unique profile regarding environmental occurrence, exposure, uptake, metabolism and kinetics, i.e. tissue distribution and toxicity to the nervous system. In the risk assessment, all these factors need to be considered. Analysis of the environmental profile for all possible sources of metals with neurotoxic properties found in ALS CSF is beyond the scope of this report but can be extracted from the Handbook on the Toxicology of Metals [56] .
In our study, the ALS cases with the highest CSF concentrations of a metal with neurotoxic properties also demonstrated high concentrations of other metals with neurotoxic properties (Fig. 5) . ] who also showed high concentrations of Al, As, Cd, Hg and Mn. These patterns of multiple occurrences of high concentrations of metals with neurotoxic properties in the same patient were not present in the plasma samples where peak concentrations were more scattered.
Among the individuals (n08) with U concentrations below the detection limit in plasma, all had low (below overall mean +1SD) however detectable concentrations in CSF. Those with elevated plasma U values had the higher corresponding values in CSF, and they were all ALS cases. The ALS case [ALS 422] with the highest plasma U concentration (0.0093 μg/L) showed the second highest (0.0126 μg/L) CSF-U concentration. Barrier protection from U seems to be limited.
No single metal has been shown to be exclusively responsible for the nerve cell deterioration in ALS. Yet, unknown combinations or synergistic effects from many metals may provide explanations to the neurodegeneration in ALS that one single metal cannot (Fig. 5) .
When all metals in the first group (i.e. U, Mn, Pb, Al, Cd, Cu, Co, Zn and V) were considered together, a highly significant separation between the ALS patients group and the control group could be observed: number of ALS cases at or above 1SD for Group 1 elements, mean02.53 [95 % CI (1.097, 3.962)]; number of controls at or above 1SD for Group 1 elements, mean00.20 [95 % CI (−0.252, 0.652)]; unequal t test, P00.0038.
Increased concentrations of the metals found to be significantly elevated in ALS cases compared to controls (Figs. 1 and 2) can be detected in air, water and soil from many varied sources forming a complex web of possible exposures. An increased number of combustion engines or increased use of metals in electronics industries or metals in pharmaceutical preparations or implants may contribute. Combined metal exposures form a complex mixture that is relevant in the search for causes to neurodegenerative disease.
Limitations of Study
The total number of individuals in this study is low; however, large amounts of data are accumulated for each individual from metals and from protein fractions. Some volunteering medical students are included in the control material, and this skews the age distribution among controls downwards, and proper age matching has not been possible. For further studies in this area, recruitment of elderly controls, although hard to find, is advisable. One case (Sample ID 870) developed clinical and laboratory signs of concomitant multiple sclerosis and was excluded. It will be covered in a separate case report. Three plasma samples (Sample ID 200, 202 and 852), two cases and one controls, were lost due to precipitation and freezing problems.
Conclusion
In summary, statistically significantly elevated concentrations of several metals with neurotoxic properties were measured in CSF from patients with ALS. Synergistic effects can be expected. We propose that the combined toxic effects of these metals contribute to the relentless course of ALS.
